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Background: Crizotinib, an oral tyrosine kinase inhibitor that tar-
gets anaplastic lymphoma kinase, has proven to offer sustained 
progression-free survival in anaplastic lymphoma kinase–rearranged 
non–small-cell lung cancers. Occurrence of severe interstitial lung 
disease (ILD) was one of the crucial adverse events reported in ran-
domized clinical trials and case reports.
Methods: In September 2011, we observed a crizotinib-associated ILD 
case. Following this index case, we reviewed the clinical and computed 
tomographic scan features of all patients treated with crizotinib in our 
department, between October 2010 and July 2013, comparing patients 
with and without ILD. A systematic literature review was performed.
Results: During this period, 29 patients were treated with crizotinib, 
five of whom developed ILD, in addition to the index case. Two types 
of adverse lung reactions may be observed in patients undergoing 
crizotinib therapy. The first is a severe, usually fatal, ILD that occurs 
during the first month of treatment (n = 1). The second is a less severe 
ILD, occurring later in time (n = 5). It occurs gradually with only few 
clinical symptoms, but predominant ground-glass opacities on com-
puted tomography, along with an intensive lymphocytic alveolitis in 
bronchoalveolar lavage fluid. These cases had a longer response with 
a median progression-free survival duration at 19.9 months (17.9–
23.5) compared with 6.2 months (1.2–13.6) for controls (p = 0.04).
Conclusion: Forty-nine cases of crizotinib-associated ILD have been 
identified by the systematic review of the literature, including our six 
cases. Two types of adverse lung reactions may be observed with dif-
ferent presentation, prognosis, and treatment. Their potential mecha-
nisms should be clarified. Nine patients with the less severe form of 
ILD were safely retreated.
Key Words: Crizotinib, Echinoderm microtubule–associated pro-
tein-like 4-anaplastic lymphoma kinase, Interstitial lung disease, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2015;10: 1148–1155)
An aberrant gene fusion echinoderm microtubule–associ-ated protein-like 4-anaplastic lymphoma kinase occurs in 
2% to 7% of worldwide non–small-cell lung cancers (NSCLC), 
encoding a cytoplasmic chimeric protein with constitutive 
kinase activity. In France, ALK rearrangement detected by 
fluorescence in situ hybridization (FISH) is observed in 3.7% 
of patients with advanced nonsquamous NSCLC.1 The preva-
lence of ALK rearrangement is increased in young nonsmoker/
light-smoker and adenocarcinoma patients. Crizotinib, an oral 
small-molecule tyrosine kinase inhibitor targeting ALK, MET, 
and ROS1 tyrosine kinases, has proven to exhibit a marked 
antitumor activity in ALK-rearranged NSCLC. Its efficacy has 
been evaluated in three multinational trials, namely two uncon-
trolled phase I/II and II studies (PROFILE 10012 and PROFILE 
10053) and a randomized controlled phase III study comparing 
crizotinib with single-agent pemetrexed or docetaxel in previ-
ously treated patients (PROFILE 10074). The drug’s efficacy 
has been recently confirmed in a randomized controlled phase 
III study comparing crizotinib with cisplatin/pemetrexed dou-
blet chemotherapy in first-line setting (PROFILE 1014).5 These 
results have led to crizotinib approval for first-line and second- 
or more-line treatment of ALK-positive advanced NSCLC 
patients in the United States and Europe, respectively.
Crizotinib was generally well tolerated in the PROFILE 
studies, most adverse events being of grade 1 or 2 sever-
ity.6,7 The most frequent grade 3 or 4 adverse events of any 
cause under crizotinib were neutropenia (7%) and elevated 
alanine aminotransferase levels (5%).6 Occurrence of severe 
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interstitial lung disease (ILD) was one of the crucial adverse 
events described. Across clinical trials (n = 1397), 34 patients 
(2.4%) had any grade ILD, 13 patients (0.9%) had grade 3 
or 4, and seven patients (0.5%) had fatal cases. These cases 
generally occurred within 2 months after the initiation of 
treatment.5,7 Food and Drug Administration therefore recom-
mended to monitor patients for pulmonary symptoms indica-
tive of ILD/pneumonitis, to exclude other potential causes of 
ILD/pneumonitis, and to permanently discontinue crizotinib 
in patients diagnosed with drug-related ILD/pneumonitis.7
In September 2011, we observed a case of crizotinib-
associated ILD that led to temporary crizotinib interruption, 
followed by reintroduction. After this index case analysis, we 
decided to review clinical characteristics and thoracic com-
puted tomographic (CT) scans of all patients treated with 
crizotinib at our institution between October 2010 and July 
2013. This article sought to compare patients with and without 
ILD and to perform a systematic review of the literature.
PATIENTS AND METHODS
In September 2011, a case of crizotinib-associated ILD 
was diagnosed in our Chest Department. All patients with diag-
nosed ALK-positive advanced-stage NSCLC detected using 
FISH (Vysis LSI ALK Dual Color, Break Apart Rearrangement 
Probe, Abbott Molecular, Des Plaines, IL) (M.A.) and receiving 
crizotinib between October 2010 and July 2013 in our institu-
tion were retrieved through the pharmaceutical database (J.F.F.). 
Crizotinib was delivered by our hospital pharmacy in the set-
ting of the PROFILE 1005, 1007, and 1014 trials (n = 11), with 
individual and cohort temporary authorizations for use (n = 
11) and European Medicines Agency authorization (Xalkori, 
Pfizer, New York, NY) (n = 7). The following characteristics 
were collected for each patient before crizotinib exposure: age, 
gender, smoking habits, performance status (World Health 
Organization), comorbidity (especially previously known ILD 
before crizotinib exposure), prior chemotherapy regimens, and 
other concomitant therapies.
All patients underwent baseline tumor assessment with 
body CT scan, including the brain, in the month before crizo-
tinib initiation, followed by further assessments every 6 to 
12 weeks until progression or death, in accordance with per-
protocol or good clinical practice recommendations. A fluo-
rodeoxyglucose-positron emission tomography (FDG-PET) 
CT was also carried out before treatment and in the event of 
suspected disease progression. The patients were monitored 
until January 31, 2014.
Definition of Cases
The diagnostic criteria of crizotinib-associated ILD 
were as follows: (1) there should be a history of drug expo-
sure; (2) the clinical, imaging, and pathological pattern of 
lung involvement should conform to earlier observations with 
the drug; (3) other etiologies of ILD should be ruled out; (4) 
improvement should follow discontinuation of the suspected 
drug; and (5) symptoms should recur upon re-challenge.8
All lung CT scans of each patient were reviewed by 
consensus by two specialists (P.C. and J.C.). ILD was defined 
by the occurrence of new and diffuse lung parenchymal 
abnormalities, including ground-glass opacities (GGO), con-
solidations, and reticulations (fine intralobar and coarse), on 
sequential CT scan examinations, according to the recommen-
dations of the Fleischner Society.9
Extensive assessments aimed at identifying the cause of 
ILD were conducted, whether cardiogenic, infectious, inflam-
matory, or related to tumor progression. Echocardiography 
as well as extensive microbiologic and autoimmune evalua-
tions (including antinuclear antibody, anti-DNA antibody, 
antineutrophil cytoplasmic antibody, C3 and C4 complement 
components, rheumatoid factor, anti-cyclic citrullinated pep-
tide antibody, and anti-aminoacyl-tRNA-synthetase antibody 
including precipitin line (PL) 1, 7, and 12) were performed 
in all patients. The serologies for domestic exposure hyper-
sensitivity pneumonitis were also performed. Some patients 
received antibiotics as a therapeutic test before fiberoptic 
bronchoscopy was carried out. Fiberoptic bronchoscopy with 
bronchial and transbronchial biopsies and bronchoalveolar 
lavage (BAL) was conducted when possible to further char-
acterize ILD and assess whether NSCLC lung progression 
had occurred. All other drugs given concomitantly to crizo-
tinib were reviewed for each of the patients and their potential 
attributed lung toxicities after querying the Pneumotox data-
base (http://www.pneumotox.com).
The study was conducted in accordance with the French 
law, which does not require approval of an Institutional 
Review Board or individual patients’ consent for such obser-
vational, noninterventional, and retrospective analyses of 
medical records.
Statistical Analyses
Analyses were performed using SAS Version 9.3 (SAS 
Institute, Cary, NC). Median and interquartile range values 
were provided. The threshold value for statistical significance 
was set at 0.05. Univariate analyses comparing the case and 
control groups were done using Wilcoxon–Mann–Whitney 
test for continuous variables and Fisher’s exact test for cat-
egorical data. Cumulative long-term survival curves were 
analyzed by means of the Kaplan–Meier method. Multivariate 
logistic regression models were constructed to identify inde-
pendent risk factors associated with ILD.
Systematic Literature Review
A systematic search of Medline accessed through 
PubMed, Embase, Cochrane databases, and Google Scholar 
was performed from inception through January 2015. We 
included all case reports of crizotinib-associated ILD pub-
lished as full-text articles or as meeting abstracts. There was 
no restriction on the language of publication when search-
ing the electronic databases. Articles were identified using a 
combination of the following search terms: “crizotinib” AND 
“Lung Diseases, Interstitial.”
RESULTS
From October 2010 to July 2013, 29 patients were 
treated with crizotinib at our institution and included in the 
study cohort. Five additional cases linked to the index case 
of crizotinib-associated ILD were identified (6 of 29; 20.7%).
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Description of the Index Case
In February 2011, a 36-year-old nonsmoker male was 
diagnosed in our Chest Department with ALK FISH-positive 
Stage IV NSCLC. Total body CT scan revealed bilateral 
lung, bone, intra-abdominal lymph nodes, and multiple brain 
metastases. In February 2012, crizotinib (250 mg twice a 
day) was initiated due to disease progression after a six-cycle 
carboplatin–paclitaxel–bevacizumab regimen followed by a 
10-cycle bevacizumab maintenance therapy. This patient did 
not underwent any thoracic or brain radiotherapy. Crizotinib 
was well tolerated and resulted in partial tumor response. In 
September 2012, crepitant rales were found on chest aus-
cultation, and the patient developed a nonproductive cough. 
Compared with the last examination, CT scan showed GGO 
occurrence in the lingula and left lower lobe, while tumor 
targets remained unchanged (Fig. 1). A BAL was performed 
with the following results: 540,000 cells/ml including mac-
rophages 20%, lymphocytes 78% (CD3 cells 81%, CD4 
58%, and CD8 38%), polymorphonuclear neutrophils 1%, 
and eosinophils 1%. Transbronchial biopsies did not find any 
tumoral lesions, and FDG-PET confirmed the persistence of 
a partial tumor response. The serologies for domestic expo-
sure hypersensitivity pneumonitis were negative, as were the 
results of autoimmunity tests (Patients and Methods section). 
To confirm the diagnosis of drug-associated ILD, crizotinib 
was discontinued for 3 weeks. At this time, GGO slightly 
improved on CT, whereas the intense lymphocytic alveolitis 
persisted. Crizotinib was then reintroduced at the same posol-
ogy and without corticosteroids. During the 16-month follow-
up, the patient remained clinically asymptomatic while taking 
crizotinib 250 mg twice a day. Sequential CT scan confirmed 
the tumor partial response; GGO decreased in the left lower 
lung, disappeared in the lingula, and then occurred in right 
upper lobe, before finally disappearing from this lobe by the 
last evaluation.
Comparison between Patients 
with and without ILD
Patients were stage IV and displayed two or more meta-
static localizations. They received one to four chemotherapy 
lines before crizotinib treatment was started at 250 mg twice 
a day. No patient underwent any thoracic radiotherapy. At the 
cutoff date, after a median follow-up of 34 (24–42) months, 14 
of 29 patients had died, with a median overall survival (OS) 
of 21 (10.7–36) months and a progression-free survival (PFS) 
of 8.5 (1.4–17.5) months on crizotinib therapy. Baseline char-
acteristics did not differ between the six cases and 23 patients 
without ILD (Table 1), yet the median duration of crizotinib 
exposure was longer in cases than others (19.9 [17.9–23.5] 
versus 6.2 [1.2–13.6] months for patients with and without 
ILD, respectively, p = 0.03). In January 2014, three cases 
(50%) and seven patients without ILD (30.4%) were still 
treated with crizotinib (p = 0.63). There was no difference in 
the frequency and severity of adverse effects between patients 
with and without ILD. At this time, one case (16.7%) and 13 
patients without ILD (56.5%) had died (p = 0.17). The median 
OS duration was not reached for cases and was at 19.1 months 
(10.3–32) for others. Median PFS duration on crizotinib was 
19.9 months (17.9–23.5) and 6.2 months (1.2–13.6) for cases 
and others, respectively (p = 0.04) (Fig. 2). A multivariate 
logistic regression model did not identify independent risk 
factors associated with ILD.
February 2013
September 2012
August 2013
A B
C D
FIGURE 1.  CT scans of index case. 
A and B, First CT scan at the diagno-
sis of ground-glass opacity and the 
presence of ground-glass opacity 
in the lingula. C, Complete disap-
pearance of GGO in the lingula. 
D, Occurrence of GGO in the right 
upper lobe but not in the lingula. 
CT, computed tomography; GGO, 
ground-glass opacity.
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Description of Crizotinib-Associated ILD
All crizotinib-associated ILD cases displayed a favor-
able outcome without requiring permanent crizotinib 
discontinuation, except for one patient who died precociously. 
The death occurred in a 74-year-old nonsmoker female who 
presented with reversible ILD after receiving erlotinib therapy 
TABLE 1.  Baseline Characteristics of the Study Population
Characteristics
Global Cohort 
(n = 29)
Patients with ILD 
(n = 6)
Patients without ILD 
(n = 23)
p (1 vs. 2)1 2
Age at diagnosis in yr, median [IQR] 54 [45–65] 50 [37–65] 57 [45–65] 0.5
Gender, n (%)
  Male 13 (44.8) 3 (50) 10 (43.5) 1
  Female 16 (55.2) 3 (50) 13 (56.5)
Smoking, n (%)
  Current and former smoker 9 (31) 1 (16.7) 8 (34.8) 0.63
  Nonsmoker 20 (69) 5 (83.3) 15 (65.2)
ECOG performance status, n (%)
  0–1 26 (89.7) 6 (100) 20 (87) 1
  2–3 3 (10.3) 0 (0) 3 (13)
Underlying pulmonary disease, n (%)
  COPD 1 (3.4) 0 1 (4.5) 0.31
  ILD 1 (3.5) 1 (16.7) 0
  Pulmonary metastasis 17 (58.6) 4 (66.7) 13 (56.6)
  Pleural metastasis 10 (34.5) 4 (66.7) 6 (26)
No. of treatment lines before crizotinib, median [IQR] 2 [1–3] 1.5 [1–2] 2 [1–3] 0.93
Duration of crizotinib therapy (mo), median [IQR] 8.5 [1.4–17.5] 19.9 [17.9–23.5] 6.2 [1.2–13.6] 0.03
Crizotinib posology decrease, n (%) 8 (27.6) 1 (16.7) 7 (30.4) 0.64
Adverse effects of crizotinib, n (%)
  Transaminase elevation 2 (6.9) 1 (16.7) 1 (4.3) 0.46
  Digestive disorders 12 (41.4) 4 (66.7) 8 (34.8)
  Visual disorders 10 (34.5) 1 (16.7) 9 (39.1)
  Edema 5 (17.2) 1 (16.7) 4 (17.4)
ILD, interstitial lung disease; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; COPD, chronic obstructive pulmonary disease.
Probability of progression-free-survival
Patients with ILD n=6
Patients without ILD n=23
Patients with ILD n=6
Patients without ILD n=23
months
log-rang test p=0.046
Probability of survival
log-rang test p=0.118
months
PFS OS
FIGURE 2.  Kaplan–Meier curves for cases (n = 6) and controls (n = 23). Progression-free survival on crizotinib (left panel). 
Overall survival (right panel). ILD, interstitial lung disease; OS, overall survival; PFS, progression-free survival.
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without any tumor response, before ALK rearrangement was 
identified (case 6). On day 28 after crizotinib initiation, she 
suddenly experienced acute respiratory distress syndrome 
(ARDS); an autopsy could not be conducted.
The five other cases exhibited similar features, summa-
rized in Table 2. None of them presented ILD before crizotinib 
initiation. ILD occurred several months after crizotinib initia-
tion (median, 8.5 [6.5–11.5] months). Diagnosis was based 
on follow-up CT scan in three patients who were clinically 
asymptomatic. One patient suffered from dry cough without 
dyspnea and fever, whereas another presented with a rapid 
onset, mimicking acute pneumonia. In this latter case, cutane-
ous vascularitis, arthralgia, and bilateral pleural effusion were 
also present and led to the diagnosis of drug-induced systemic 
lupus erythematosus (case 2, see Table 2 for autoimmunity). 
In the four other patients, autoimmune evaluation remained 
negative (Table 2). Lung CT scan revealed bilateral GGO in all 
patients (Fig. 1) and consolidations in one, without superim-
posed reticulation. Only one patient exhibited bilateral pleural 
effusion (case 2). Over time, the opacities tended to improve 
more or less completely and migrate from one lobe to another. 
One patient refused to undergo extensive pulmonary evalua-
tion. BAL, carried out for the four other patients, showed a 
T-lymphocytic alveolitis with a predominant CD4 cell subset. 
Microbiological evaluation proved negative for virus, bacte-
ria, fungi, and parasites. Tumor evaluation, including a total 
TABLE 2.  Description of Patients with Ground-Glass Opacity Pattern Interstitial Lung Disease
Patient (Age at Diagnosis, Years; Gender)
Index Case  
(37, Male)
Case 2  
(48, Female)
Case 3  
(51, Female)
Case 4  
(65, Male)
Case 5  
(33, Male)
Treatments before 
crizotinib 
(number of 
cycles)
L1: CarboPacli Beva (6), 
maintenance: Beva 
(10); L2: Crizotinib
L1: CarboPacli (6); 
L2: Pem (3); L3: 
Crizotinib
L1: CisPem (6), 
maintenance: Pem 
(6); L2: Docetaxel; 
L3: Crizotinib
L1: CarboPacli (6); 
L2: Pem (6); L3: 
Gemcitabine (4); 
L4: Erlotinib; L5: 
Crizotinib
L1: Cispem (4);  
L2: Crizotinib
Delay of 
symptoms 
occurrence 
(mo)
7 21 10 6 2
CT scan GGO in lingula and LLL GGO in ML and RLL Two area of GGO in 
RLL
GGO in lingula Consolidations with  
GGO in RUL
FDG-PET PMR PMR PMR NA PMR
Bronchoalveolar 
lavage
540,000 cells/ml: M 
20%; L 78% (CD3 
81%, CD4 58%, CD8 
38%, CD19 16%); 
N 1%; E 1%. No 
monoclonal B-cell 
population
590,000 cells/ml: M 
86%; L 12.5% (CD3 
92%, CD4 76%, CD8 
22%, CD19 2%); N 
0.5%
180,000 cells/ml: 
M 35%; L 64% 
(CD3 94%, CD4 
66%, CD8 29%, 
CD19 3%); N 1%. 
Oligoclonal aspect of 
B lymphocytes
1,000,000 cells/ml: M 
57%; L 41,5% (CD3 
70%, CD4 74%, 
CD8 26%, CD19 
8%); N 1%; E 2%; 
mastocytes 0.5%
NA
Bronchial biopsy Cicatricial tissue without 
tumor proliferation
NA Macrophage alveolitis 
without inflammation 
nor tumor cells
NA NA
Autoimmunity Negative Positive antinuclear 
antibodies; presence 
of anti-double-
stranded DNA 
antibodies; low C3 
and C4
Negative Negative Negative
Crizotinib 
treatment
Stopped 3 wk, 
reintroduction
Stopped 4 wk, 
reintroduction
Stopped 3 wk, 
reintroduced at 
200 mg twice a day
Continued Continued
Associated 
treatments
None Corticosteroids 40 mg, 
progressively 
decreased to 5 mg
Antibiotics Antibiotics Antibiotics, 
corticosteroids 40 mg 
progressively decreased 
to 5 mg
Initial evolution Regression of GGO Regression of ILD Regression of GGO Regression of GGO Regression of ILD
Long-term 
evolution
Complete resolution in 
lingula and LLL, but 
recurrence in RUL 11 
mo later
Recurrence of right 
GGO 7 mo later
Relapse of ILD (same 
localization) 1 yr later 
leading to increased 
corticosteroid posology
CarboPacli Beva, carboplatin paclitaxel bevacizumab; Cis Pem, cisplatin pemetrexed; CT, computed tomography; GGO, ground-glass opacity; LLL, left lower lobe; ML, 
middle lobe; RLL, right lower lobe; RUL, right upper lobe; FDG-PET, fluorodeoxyglucose-positron-emission tomography; PMR, partial metabolic response; NA, not applicable; M, 
macrophages; L, lymphocytes; N, neutrophil polymorphonuclears; E, eosinophil polymorphonuclears.
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body CT scan and FDG-PET scan, did not reveal tumor pro-
gression to occur concomitantly to ILD diagnosis. Table S1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A841) listed all other drugs given concomitantly to crizotinib 
for each of the patients and their potential attributed lung tox-
icities after querying the Pneumotox database (http://www.
pneumotox.com). We have also excluded environmental expo-
sures (data not shown).
Crizotinib was temporarily stopped in three patients and 
then reintroduced in all three, along with corticosteroids in 
one of them (case 2, 5 mg prednisone for lupus). Crizotinib 
was continued in two patients, in association with corticoste-
roids in one of them. Antibiotics when given had no effect 
(Table 2). No patient received diuretics for hydrosaline deple-
tion. Long-term follow-up revealed three GGO relapses.
Results of Systematic Review
After a systematic review of the literature, we identified 
43 other cases of crizotinib-associated ILD, among which 34 
were notified in the PROFILE studies and nine case reports 
described in more detail10–18 (Table 3).
DISCUSSION
In the present series, we reported six cases of crizotinib-
associated ILD (20.7%) among 29 patients with advanced 
ALK-rearranged NSCLC treated by crizotinib. This frequency 
was much greater than in crizotinib registration studies (2.4%). 
Our opinion is that asymptomatic patients with occurrence of 
GGO on CT scan were not reported as crizotinib-associated 
ILD in these studies. In our cohort, there were finally only two 
cases of ≥3 grade ILD that is 7%. Case 6 was a fatal ILD and 
case 2 was a grade 3 ILD, in the context of a drug-induced sys-
temic lupus erythematosus. By contrast, the four other cases 
were diagnosed by a secondary re-reading of the thoracic CT 
scans. The patients were asymptomatic or had very few symp-
toms, as it has been recently described by Asai et al.14
Two types of crizotinib-associated ILD seem to exist. 
The first is severe, irreversible, requires the immediate stop of 
crizotinib, and is fatal in most of the cases, in line with one of 
our cases (case 6). Previous reports have already documented 
severe ILD/ARDS resulting in death early (<2 months) after 
crizotinib initiation, which suggests a potential direct drug-
toxic effect7,10,11,15,18 (Table 3). CT scan showed a rapid and 
bilateral widespread of GGO, with a final pathology diagno-
sis of diffuse alveolar damage in most of the cases (Table 3).8 
The second type is less severe, reversible, and may not need a 
definitive crizotinib withdrawal, in line to our index case and 
four of our other cases. It occurred later after crizotinib intro-
duction (median, 8.5 [6.5–11.5] months). Patients were either 
mildly symptomatic or clinically asymptomatic. CT scan 
showed a predominant/exclusive GGO pattern of ILD (GGO-
ILD), which was localized and faint. Other reported cases had 
few symptoms like ours (Table 3).14,16,17 Crizotinib was restarted 
with corticosteroids,12,16,17 except in one case.14 This latter being 
the only which presented a relapse. In our study, GGO-ILD 
favorably evolved without requiring long-term crizotinib cessa-
tion or high-dose corticosteroid use. In total, nine patients (four 
described in the literature12,14,16,17 and five of our cases) were 
safely retreated. Finally, GGO-ILD seems to be associated with 
long-term control of disease progression, which made us reflect 
on the mechanism(s) of GGO-ILD occurrence.
A GGO pattern within the lung is not a common feature 
of ALK-rearranged NSCLC.19 In a recent CT scan series of 
36 ALK-positive patients, masses and nodules were observed 
in more than 40% of cases, and lymphadenopathy in 86.1%, 
while only one patient displayed GGO lesions. Similarly, other 
groups20,21 found that most ALK-positive tumors showed a solid 
growth and lymphangitic pattern without GGO on CT. In our 
patients, the GGO lesions were not near the tumoral lesions, 
but at distance in normal lung, and tended to migrate over time. 
We also carefully investigated our patients by PET CT scan 
and fiberoptic bronchoscopy with BAL to eliminate disease 
progression. In addition, we did not identify any concomitant 
pulmonary infection, environmental hypersensitivity pneu-
monitis, or interstitial pneumonia with autoimmune features22 
(Table 2). We made a close study of other concomitant drugs 
to exclude other causes of drug-related ILD (http://www.pneu-
motox.com) (Table S1, Supplemental Digital Content 1, http://
links.lww.com/JTO/A841). Finally, GGO decreased at least 
partially after stopping crizotinib with or without corticoste-
roids administration, which strongly suggests crizotinib imput-
ability. Altogether, these findings indicate that GGO-ILD was 
associated with crizotinib exposure (Table S2, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A841).
Other arguments suggest that crizotinib-associated ILD 
could be accounted for by a crizotinib-related hypersensi-
tivity pneumonitis. The relatively long delay of occurrence 
(necessary for drug sensitization), resolution after crizotinib 
cessation, and re-occurrence after crizotinib reintroduction 
emphatically point to a hypersensitivity mechanism. In case 2, 
the observation of a systemic erythematous lupus with bilat-
eral pleural effusion concomitant to GGO-ILD recognition 
was also very indicative of a drug-related immune mecha-
nism.23 Moreover, the GGO pattern on thoracic CT scan and 
the intense lymphocytic alveolitis observed in BAL fluid, 
without any pathogens, are both hallmarks for hypersensi-
tivity pneumonitis, whether environmental or drug-related.24 
Finally, such a hypersensitivity pneumonitis has been previ-
ously reported to occur with other cancer drugs,25,26 including 
cytotoxic agents,27 antibodies,28 and small molecules.29,30
Alternatively, several arguments could suggest that GGO-
ILD reflected an effective immune antitumor response that was 
favored or elicited by crizotinib treatment. In all cases, this phe-
nomenon occurred at a late time point after crizotinib introduc-
tion. The tumors were responding to crizotinib at the time of 
ILD occurrence. The duration of response seemed to be lon-
ger than that in patients without ILD, with a higher PFS (19.9 
versus 6.2 months, p = 0.04). The mortality also seemed to be 
lower, with a median OS duration not achieved for the five cases 
at the cutoff time, after a 1.5- to 7-year postdiagnosis follow-
up. However, these findings must be interpreted with caution in 
regard to the retrospective character of the analysis and the low 
number of patients included in the cohort. Moreover, an effec-
tive immune antitumor response was suggested by circulation 
of specific anti-ALK, B cells, and cytotoxic T cells observed in 
patients with ALK-positive anaplastic large cell lymphoma but 
Copyright © 2015 by the International Association for the Study of Lung Cancer
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not in those with ALK-negative lymphoma.31,32 Furthermore, 
such a specific immune response was associated with a more 
limited disease at diagnosis, a lower number of circulating 
tumor cells, and a lower probability of relapse after remis-
sion.33,34 Finally, we hypothesize that GGO-ILD is a late event 
occurring in patients with ALK-rearranged NSCLC responding 
to crizotinib and could reflect an effective immune response to 
ALK-rearranged tumor cells.
CONCLUSION
In conclusion, our observations and the review of the 
literature suggest that at least two types of adverse lung reac-
tions may occur in patients treated by crizotinib. On the one 
hand, GGO has an early onset after exposure to the drug. GGO 
is diffuse and spreads rapidly in both lungs finally resulting for 
an ARDS, usually fatal despite discontinuation of the drug. 
Corticosteroids are ineffective. On the other hand, GGO has 
a late onset, is rather localized faint in normal lung far from 
tumoral lesions, and migrate with time. The course is usually 
favorable after discontinuation of the drug. The interest of cor-
ticosteroids to accelerate the healing is uncertain. These two 
forms are described as “diffuse alveolar damage pattern” for 
the first and as “hypersensitivity pneumonia pattern” for the 
second. This GGO-ILD may be rather common if searched for 
by the clinician. Crizotinib in this setting should therefore be 
continued with careful lung monitoring, if no tumor progres-
sion has been identified after a full assessment.
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